Vitae Pharmaceuticals (VTAE) and Its Peers Critical Review
Vitae Pharmaceuticals (NASDAQ: VTAE) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its competitors? We will compare Vitae Pharmaceuticals to related companies based on the strength of its earnings, dividends, institutional ownership, analyst recommendations, valuation, profitability and risk.
Valuation and Earnings
This table compares Vitae Pharmaceuticals and its competitors top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Vitae Pharmaceuticals Competitors||$579.31 million||$242.01 million||-6.35|
Vitae Pharmaceuticals’ competitors have higher revenue and earnings than Vitae Pharmaceuticals. Vitae Pharmaceuticals is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent recommendations for Vitae Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Vitae Pharmaceuticals Competitors||190||911||1684||67||2.57|
As a group, “Biopharmaceuticals” companies have a potential upside of 4.10%. Given Vitae Pharmaceuticals’ competitors stronger consensus rating and higher possible upside, analysts clearly believe Vitae Pharmaceuticals has less favorable growth aspects than its competitors.
Risk & Volatility
Vitae Pharmaceuticals has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Vitae Pharmaceuticals’ competitors have a beta of 1.24, suggesting that their average stock price is 24% more volatile than the S&P 500.
This table compares Vitae Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Vitae Pharmaceuticals Competitors||-13,073.01%||230.15%||-22.89%|
Insider and Institutional Ownership
72.6% of Vitae Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.3% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 14.8% of Vitae Pharmaceuticals shares are owned by insiders. Comparatively, 13.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Vitae Pharmaceuticals competitors beat Vitae Pharmaceuticals on 9 of the 11 factors compared.
About Vitae Pharmaceuticals
Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer’s disease, or Alzheimer’s. VTP-43742, the Company’s wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.
Receive News & Ratings for Vitae Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitae Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.